Table 4.

Intrahost variation in spike sequence detected in immunocompromised patients not receiving nAb-based treatments.

Age/Sex (Identifier)	Condition	Antiviral Treatments	SARS-CoV-2 Strain	Spike Mutations	First Detected at Day	Outcome	Ref
47/F	diffuse large B cell lymphoma (rituximab plus polychemotherapy)	n.a.	B.1.1.163	Y453F, ΔHV69–70, S50L, ΔLGVY141–144, T470N, and D737G	120	negative PCR on day 132	Bazykin et al. [7]
61/F	diffuse large B cell lymphoma stage IVB	remdesivir for 10 days, high-dose steroids for 7 days	B.1.1.401	V3G, S50L, N87S, A222V, ΔLTTRTQLPPAYTN18–30 and ΔLGVY141–144	164	negative PCR at day 197	Borges et al. [45]
3/F (1)	B-cell acute lymphoblastic leukemia (chemotherapy)	n.a.	20C	silent I410I (22792:C/A)	27	negative PCR at day 91	Truong et al. [37]
2/M (3)	B-cell acute lymphoblastic leukemia	remdesivir for 5 days	20C	V483A and E484Q	139	negative PCR at day 196
				V70P, ΔLGV141–143, N440K	162
37/F	advanced HIV and antiretroviral treatment failure	dexamethasone	B.1.1.273	E484K	6	negative at day 233	Karim et al. [46]
				K417T and F490S	71
				L455F and F456L	106
				D427Y and N501Y	190
80/M	chronic lymphocytic leukemia and hypogammaglobulinemic	remdesivir days 213–230, REGN-COV-2 day 265	B.52	L179	58	negative PCR day 311	Kavanagh Williamson et al. [47]
				S255F, S477N, H655Y, D1620A, ΔHV69–70	155
40/M	autologous hematopoietic stem cell transplant due to a diffuse large B-cell lymphoma	IVIg	B.1.128	ΔLGV141–143 → ΔLGVY141–144		negative PCR on day 196	Mendes-Correa et al. [44]
n.a./n.a.	transplant recipient	remdesivir	n.a.	S13I, T95I, E484G, F490L, ΔLGVY141–144, ΔLHRS244–247, and ΔSPRRARSV680–687	n.a.	n.a.	Weigang et al. [48]
n.a./n.a.	18 B-cell non-Hodgkin lymphoma	44% CCP 37% remdesivir	n.a.	n.a.	requested	n.a.	Lee et al. [49]